Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), has recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Baird sold ...